Celyad SA (CYAD) Announces Completion of NKR-2 Phase I in AML
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Celyad (Nasdaq: CYAD) announced the successful completion of the 21-day safety follow-up of the last patient enrolled at the fourth dose level in its Phase I clinical trial evaluating the safety and feasibility of its NKR-2 T-cell therapy - in Acute Myeloid Leukemia and Multiple Myeloma patients. No safety issues or toxicities were reported.
Dr. Christian Homsy, CEO of Celyad: “We are pleased that no adverse safety signal has been reported. Based on the successful completion of the fourth cohort, we are looking forward to starting the global Ph I/IIa multiple dose trial, in the US and EU, of our NKR-2 autologous therapy in the fourth quarter of this year.”
Dr. Frédéric Lehmann, Head of Immuno-Oncology at Celyad: “The absence of any safety or toxicity signal up to this point continues to support our belief that this unique engineered T-cell construct can be safely administered and potentially lead to a therapeutic effect providing hope to the thousands of patients who need better treatments for both AML and MM.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB) Announces U.S. FDA, EMA Acceptance of Nusinersen Regulatory Applications
- The First Of Long Island (FLIC) Announces Three-for-Two Common Stock Split
- Sanofi (SNY) Alerts Regeneron (REGN) of FDA Concerns Related to Sarilumab Manufacturing Facility
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!